Skip to main content

Technology & AI

Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry Platform

By GlobeNewswire Source: Financial Post
Pathos AI Acquires Majority Stake in DeuterOncology to Advance Next-Generation MET Inhibitor Identified by Pathos Foundry Platform

Pathos AI has acquired a majority stake in DeuterOncology to advance a next-generation MET inhibitor discovered through Pathos's AI-powered drug development platform. The acquisition represents one of the first clinical-stage oncology deals sourced and evaluated entirely through an AI-driven approach. The MET inhibitor candidate is being developed to treat MET-driven cancers with improved efficacy and safety profiles.

Read Full Article at Financial Post

Related Articles